Immunohistochemical analysis of tumor budding in stage II colon cancer: exploring zero budding as a prognostic marker.

ABSTRACT: Tumor budding, a biomarker traditionally evaluated using hematoxylin and eosin (H&E) staining, has gained recognition as a prognostic biomarker for stage II colon cancer. Nevertheless, while H&E staining offers valuable insights, its limitations prompt the utilization of pan-cytokeratin immunohistochemistry (IHC). Consequently, this study seeks to evaluate the prognostic significance of tumor budding using IHC in a contemporary cohort of stage II colon cancer patients, aiming to deepen our understanding of this critical facet in cancer prognosis. We conducted a retrospective, population-based cohort study including 493 patients with stage II colon cancer and evaluated tumor budding using IHC, following the H&E-based guidelines proposed by the International Tumor Budding Consensus Conferenc

SUBMITTER: Pihlmann Kristensen M 

PROVIDER: S-EPMC11522105 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature